IMV

Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX
VENTURE:IMV), a clinical stage vaccine and immunotherapy company, has elected
Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is
effective immediately. 


Dr. Keltner, a consultant to IMV since early 2013, has helped to raise the
profile of the company in the US and Europe in the fast-evolving world of cancer
immunotherapy. He also serves as chairman of Raptor Pharmaceuticals Corp
(NASDAQ:RPTP), a $900 million commercial stage biotechnology company based in
California. 


Albert Scardino, Executive Chairman, said: "Dr. Keltner shares our goal, to put
effective cancer treatments to work in patients. Whether advising investment
banks, fund managers, large pharmaceutical companies or clinical stage companies
such as ours, he has proved effective at matching up financial investment with
promising science."


Dr. Keltner said: "Immunovaccine has developed a pivotal piece in the evolving
field of cancer therapy. In early human trials in ovarian and breast cancer, its
unique vaccine technology has shown an ability to stimulate powerful immune
responses that may delay the recurrence of cancers. In combination with other
therapies, IMV's treatments may help turn cancer into a treatable, long-term
illness. Now that immunotherapy has captured the imagination of both the
scientific and the investment communities, it is important that we introduce the
company to a wider audience."


Until 2013, Dr. Keltner was chief executive of AgonOx, a private US biotech
company working to develop OX40 agonists for use in cancer therapy. At AgonOx,
he engineered a partnership with Medimmune LLC, the global biologics arm of
Astra Zeneca PLC, to advance the private company's immune system activators. 


Dr. Keltner also holds positions on the boards of Infostat, Oregon Life
Sciences, BioQuiddity, and Goodwell Technologies. EPISTAT, the consulting
company he founded in 1972, advises on international healthcare technology
transfer, corporate risk management and healthcare strategy. He serves on the
faculties of the Medical Schools at Case Western Reserve University and Columbia
University.


In conjunction with this appointment, Dr. Keltner has been granted 50,000 stock
options under Immunovaccine's Stock Option Plan, exercisable at a price equal to
$0.74 per common share. The options have a term of five years and vest over a
period of 18 months.


Immunovaccine expects three trials to be initiated in 2014 with its cancer
immunotherapies. The largest is a randomized Phase II trial of DPX-Survivac in
ovarian cancer being sponsored and conducted by Canada's NCIC Clinical Trials
Group (NCIC CTG). The trial is expected to begin enrolling the first of its 250
patients in 2014. Additionally, researchers at the University of Rome have
initiated a Phase l/II trial of DPX-Survivac in glioblastoma (brain cancer),
with the first patients receiving the vaccine in the first half of this year. A
third trial, using DPX-0907 to treat breast and ovarian cancer, is planned for
initiation at Busto Arsizio Hospital in Milan.


About Ovarian Cancer

Ovarian cancer accounts for more deaths than any other gynecologic cancer.
Symptoms do not occur until it is in the later stages of the disease, reducing
the chance for successful treatment and remission. It kills more than 100,000
women annually around the world. Improved surgical techniques have helped to
reduce the rate of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than four years. 


About Glioblastoma

Glioblastoma, the most common form of brain cancer, is a fast-growing tumor that
develops from astrocytes, a type of glial cell present in the brain. The
National Cancer Institute estimates that more than 23,000 Americans will be
diagnosed with brain and other nervous system tumors in 2014. Glioblastoma
accounts for approximately 52 percent of all brain tumors. The current standard
of care for glioblastoma patients calls for patients to receive maximum surgical
resection combined with radiation and concomitant and adjuvant temozolomide
therapy. Newly diagnosed glioblastoma patients have a median overall survival of
less than 24 months.


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Operating Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024